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Abstract
Purpose Thyroid hormone receptors (THR) have manifold functions and are involved in the carcinogenesis of several tumor 
types. Within this study, we aimed to investigate the expression pattern (nuclear versus cytoplasmic) of the THR alpha and 
its impact on patients survival in ovarian cancer (OvCa).
Methods The presence of the thyroid hormone receptors THRα, THRα1 and − 2 was investigated in 156 ovarian cancer 
samples using immunohistochemistry (IHC) using semi-quantitative immunoreactivity (IR) scores and correlated with 
clinical, pathological data, subtype of ovarian cancer, clinical data, staining of 20 already described OvCa marker proteins 
and overall survival (OS).
Results Among all subtypes of OvCa, clear cell carcinomas showed the highest THRα expression. Furthermore, nuclear 
THRα was associated with a reduced survival in this subtype. However, nuclear expressed THRα1 turned out to be a positive 
prognosticator for all subtypes of OvCa patients. Nuclear THRα2 is a positive prognosticator for OvCa patients of the serous 
subtype. In contrast, cytoplasmic expression THRα2 was associated with a reduced OS in all subtypes of OvCa patients; 
while, cytoplasmic expression of THRα1 is associated with reduced OS in mucinous OvCa patients only. In addition, THRα 
expression correlates with gonadotropin receptors, steroid hormone receptors, TA-MUC1 and glycodelin.
Conclusion Depending on nuclear or cytoplasmic expression, our study shows that THRα and its isoforms 1 and 2 provide 
different prognostic information for ovarian cancer patients. Further investigations should analyze if THRs may represent 
new endocrine targets for the treatment of ovarian cancer.
Keywords Thyroid hormone receptor · Ovarian cancer · Overall survival · Nuclear versus cytoplasmic
Background
Thyroid-stimulating hormone (TSH) regulates thyroid func-
tion by binding to its receptor (thyroid hormone receptor—
THR) expressed at the surface of thyroid cells. Recently, it 
has been demonstrated that THR is abundantly expressed in 
several tissues apart from the thyroid, among them the nor-
mal ovarian surface epithelium. The hormone dependency 
of the ovaries and the functional similarity of THRs and 
estrogen- (ER) and progesterone receptors (PR; both act in 
the nucleus as transcription factors) lead to the hypothesis 
that THRs may be a prognostic marker in ovarian cancer 
patients as demonstrated recently for breast cancer patients 
(Li et al. 2002; Rasmusson et al. 1987; Turken et al. 2003; 
Ditsch et al. 2013).
The nuclear receptors of thyroid hormones regulate the 
expression of specific cellular genes by interacting with 
distinct DNA sequences. They are ligand-activated tran-
scription factors, which regulate the transcription of target 
genes. THRs are encoded by two genes—THR alpha and 
beta—located on human chromosomes 17 and 3 (Silva et al. 
2002). They have three major isoforms: THRα1, THRα2 and 
THRβ1 (Ling et al. 2010) with high homology in amino acid 
composition. The most diversified region between THRα 
and THRβ is located in the N-terminal area, related to their 
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trans-activation activity (Lazar 1993). Recent studies discov-
ered by oligonucleotide microarray transcriptional profiling 
that THRα and THRβ mRNAs are among the most strongly 
expressed nuclear hormone receptor genes in cultured 
human ovarian surface epithelial (OSE) cells (Rae et al. 
2004). The presence of THRα1, ΤHRα2, and THRβ1 tran-
scripts in cultured OSE cells is confirmed and the presence 
of THRα and THRβ proteins in the OSE cell layer has been 
demonstrated. Although, THRα and β isoforms are encoded 
by separate genes, differential promoter usage gives rise to 
two different THRα receptors, THRα1 and THRα2 (Zhang 
and Lazar 2000). Unlike THRα1 and THRβ1, which are 
conventional ligand-activated receptors, THRα2 is a ligand-
independent negative regulator of active THRs. Thus, the 
presence of different THR isoforms, in conjunction with the 
potential for pre-receptor metabolism of thyroid hormones 
through expression of activating and inactivating deiodi-
nase enzymes, strengthens the likelihood that the OSE is 
a physiologically important thyroid hormone target tissue 
(Rae et al. 2004).
Ovulation is a recurrent inflammatory reaction caus-
ing regular and frequent local injury to the ovarian sur-
face during follicular rupture (Espey 1994; Rae and Hillier 
2005). Ovarian cancer develops when a mutation or genetic 
change—spossibly caused by repeat episodes of inflamma-
tion-associated DNA damage (Murdoch 1998; Murdoch 
et al. 1999; Beachy et al. 2004)—occurs in the cells on the 
surface of the ovaries or in the fallopian tubes and leads to 
uncontrolled cell growth that may often metastasize (Rasool 
et al. 2014). Suppression of ovulation by e.g. pregnancy, 
breast feeding, or oral contraception reduces the risk of ovar-
ian cancer, whereas diseases such as endometriosis, ovarian 
cysts, and hyperthyroidism are associated with increased 
risk (Ness and Cottreau 1999; Ness et al. 2000).
Ovarian cancer consists of four histopathological sub-
types, represents the fourth most frequent type of cancer 
among females, and is the leading cause of death from 
gynecological cancer in the western world. Besides the 
histopathological subtype, grading, clinical staging and the 
amount of residual tumor, a number of several putative prog-
nostic markers had been suggested for monitoring this dis-
ease (Ditsch et al. 2013). As ovarian cancer is also a thyroid 
hormone-dependent neoplasm (Shinderman-Maman et al. 
2016), T3 has been shown to directly exert inflammatory 
effects on ovarian surface epithelial cell function in vitro and 
activate expression of genes associated with inflammation 
(Cohen et al. 2014; Rae et al. 2007). Studies also indicate 
that T3 increases the expression of ERα, which strongly 
associates with the development of epithelial ovarian can-
cer, which may explain the epidemiological linkage between 
hyperthyroidism and ovarian cancer (Rae et al. 2007).
The current study examines possible alterations of THR 
expression in ovarian carcinomas and its implication in ovar-
ian cancer survival. Little is known about the context of thy-
roid function in ovarian carcinogenesis and the role of THR 
expression outside the thyroid is not completely understood. 
From our knowledge of therapy modalities, anti-hormonal 
therapy like tamoxifen, which unfold its effect via steroid 
hormone receptors, can be affective in ER-positive ovarian 
cancers. First in this field, our examinations focuses on the 
prognostic impact of thyroid hormone receptors of the alpha 
subtype (general alpha, alpha-1 and alpha-2, respectively) on 
pathological different ovarian cancer tissues.
Methods
Tissue samples
Tissue samples were obtained from 156 patients undergoing 
gynecological surgery for epithelial ovarian cancer (EOC) 
at the Department of Obstetrics and Gynaecology of the 
Ludwig-Maximilians-University Munich. The clinico-patho-
logical parameters are shown in Table 1. Experienced gynae-
cologic pathologists performed histopathological staining 
and evaluation according to the criteria of the International 
Federation of Gynaecologists and Obstetricians (FIGO) and 
the World Health Organization (WHO). Full slides were 
used for immuohistochemical stainings. EOC specimens 
were available in different histological subtypes: serous 
(n = 110) thereof 84 high-grade and 26 low-grade cases, 
clear cell (n = 12), endometrioid (n = 21), mucinous (n = 13). 
Patients with ovarian low malignant potential tumors (e.g., 
Borderline tumors) were excluded from the study and no 
patients had neo-adjuvant chemotherapy. Patient’s clinical 
data were available from patient charts, aftercare files and 
tumor registry database information. The main outcomes 
assessed were disease recurrence and patient survival. For 
Table 1  Clinico-pathological 
parameters of the study group 
(n = 156)
Histological subtype FIGO stage Nodal status Age (years)
High-grade serous 84 (54%) I 35 (23%) N0 56 (36%) mean 62
Low-grade serous 26 (17%) II 10 (6%) N1 54 (35%) min 33
Endometrioid 21 (13%) III 107 (69%) NX 46 (29%) max 88
Mucinous 13 (8%) IV 4 (2%)
Clear cell 12 (8%)
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survival analysis, survival time was defined as the time 
between the date of primary ovarian cancer diagnosis and 
the date of death.
Immunohistochemistry
Our group has extensively described immunohistochemistry 
of THRα, THRα1 and THRα2 on FFPE sections (Ditsch 
et al. 2012a, 2013). In brief, rabbit polyclonal antibodies 
detecting THRα (Abcam, Cambridge, UK); Zytomed, Ber-
lin, Germany), THRα1 (Zytomed) and THRα2 (Zytomed)) 
were stained by employing commercially available kits 
(Vectastain Elite rabbit-IgG-Kit (VectorLabs, Burlingame, 
CA); ZytoChem Plus HRP Polymer System (Zytomed). 
Reference sources for the used antibodies are listed in the 
Supplementary Table. Appropriate positive (struma, colon 
and placental tissue) and negative controls were included in 
each experiment (Supplementary Figure). Tissue sections 
treated with pre-immune IgGs (supersensitive rabbit nega-
tive control, BioGenex, Fremont, CA) instead of the primary 
antibody served as negative controls. Immunoreactivity was 
quantified by applying a well-established semi-quantitative 
scoring system (IR-score; also known as Remmele’s score) 
by two independent observers (gynecologic pathologists 
(E.S. and D.M.)) by consensus. This scoring method has 
already been used in numerous studies (Ditsch et al. 2012b, 
c; Lenhard et al. 2011, 2012b) of our group. The IRS quanti-
fies immunoreactivity by multiplication of optical staining 
intensity (graded as 0: no, 1: weak, 2: moderate and 3: strong 
staining) and the percentage of positive stained cells (0: no 
staining, 1: ≤ 10% of the cells, 2: 11–50% of the cells, 3: 
51–80% of the cells and 4: ≥ 81% of the cells). According 
to the previously published data, tissue samples that had 
been assigned an IRS higher than 1 were scored as positive 
(Lenhard et al. 2012a).
Statistical analysis methods
The IBM statistic package SPSS (version 25) was used to 
test data for statistical significance. Differences in THR 
expression among three or more groups were tested using 
the non-parametric Kruskal–Wallis rank-sum test and for 
pairwise comparisons using the nonparametric Mann–Whit-
ney U rank-sum test. Correlation analysis was performed 
using the Spearman correlation coefficient. Overall survival 
(years) was compared by Kaplan–Meier graphics and differ-
ences in patient overall survival times were tested for signifi-
cance using the chi-square statistics of the log rank test. For 
multivariate analyses, the cox regression model for overall 
survival was used. Data were assumed to be statistically dif-
ferent in case of p < 0.05.
Results
THRα expression according to EOC subtypes
THRα expression showed significant differences within the 
histological subtype, accounting nuclear as well as cyto-
plasmic staining. Serous carcinomas showed only faint 
expression of THRα in the nucleus (median IRS = 2) as 
well as in the cytoplasm (median IRS = 0; Fig. 1a = 10 × lens, 
Fig. 1f = 25 × lens). A more intense staining was observed in 
the clear cell cases in the nucleus (median IRS = 2) as well 
Fig. 1  a THRα expression in serous carcinoma (10 × lens). b THRα 
expression in clear cell carcinoma (10 × lens). c THRα expression 
in endometrioid carcinoma (10 × lens). d THRα expression in muci-
nous carcinoma (10 × lens). e Summary of THRα expression in dif-
ferent carcinoma subtypes (nuclear expression). f THRα expression 
in serous carcinoma (25 × lens). g THRα expression in clear cell car-
cinoma (25 × lens). h THRα expression in endometrioid carcinoma 
(25 × lens). i THRα expression in mucinous carcinoma (25 × lens). j 
Summary of THRα expression in different carcinoma subtypes (cyto-
plasmic expression)
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as in the cytoplasm (median IRS = 2; Fig. 1b = 10 × lens, 
Fig. 1g = 25 × lens). The endometrioid subtype showed simi-
lar expression schemas as the serous subtype in the nucleus 
(median IRS = 2) as well as in the cytoplasm (median 
IRS = 0; Fig. 1c = 10 × lens, Fig. 1h = 25 × lens). The lowest 
expression of THRα was found in the mucinous subtype in 
the nucleus (median IRS = 1) as well as in the cytoplasm 
(median IRS = 0; Fig. 1d = 10 × lens, Fig. 1i = 25 × lens). A 
summary of the staining results is shown in Fig. 1e for the 
nuclear staining (p = 0.005) and Fig. 1j for the cytoplasmic 
staining (p = 0.037).
THRα1 as well as THRα2 showed no significant differ-
ent expression according to the histological subtype. The 
median expression of THRα1 in the nucleus was 2 and the 
median expression in the cytoplasm was 0. The median 
expression of THRα2 in the nucleus was 6 and, therefore, 
much more intense compared to THRα and − α1, respec-
tively. The median expression of THRα2 in the cytoplasm 
was 0. There was no significant different expression of the 
three THRα subtypes according to grading, FIGO staging 
or age at surgery.
Correlation analyses
Using recently published data by our institute, we were able 
to correlate the expression of all THRα subtypes stained 
with former investigation results. There are significant cor-
relations with the gonadotropin receptors (Lenhard et al. 
2011) and the luteinizing hormone (LH)-receptor ligand 
hCG (Lenhard et al. 2012b); specifically, THRα staining 
in the nucleus showed a positive correlation to the follicle 
stimulating hormone receptor (FSHR) (correlation coeffi-
cient (cc) = 0.181; p = 0.027) and a negative correlation to 
hCG (cc = − 0.247, p = 0.003). In opposite, THRα in the 
cytoplasm showed a positive correlation with the lutein-
izing hormone/choriogonadotropin receptor (LH/hCGR) 
(cc = 0.199, p = 0.014) and a positive correlation to hCG 
(cc = 0.187, p = 0.027). The THRα1 expression in the 
cytoplasm is positively correlated with hCG (cc = 0.278, 
p = 0.001). THRα2 in the nucleus showed a positive corre-
lation to FSHR (cc = 0.185, p = 0.024). In addition, there are 
also positive correlations with the classical steroid hormone 
receptors, which were analyzed by our research group too 
(Lenhard et al. 2012a). THRα staining in the nucleus showed 
a positive correlation with the ERβ (cc = 0.213, p = 0.009) 
and with the PRα (cc = 0.172, p = 0.035). The THRα1 
expression in the cytoplasm is positively correlated with 
ERβ (cc = 0.219, p = 0.006). THRα2 in the nucleus showed 
positive correlation with ERα (cc = 0.247, p = 0.002) and 
with PRα (cc = 0.219, p = 0.007). In addition to the classi-
cal estrogen receptors, also the GPER (Heublein et al. 2014; 
Heublein et al. 2013a, b)  showed positive correlation with 
THRα staining in the nucleus (cc = 0.219, p = 0.007) and 
with THRα2 in the nucleus (cc = 0.252, p = 0.002).
Another positive correlation was found within the tumor-
associated mucin 1 epitop (TA-MUC1) detected with the 
Gatipotuzumab antibody formerly known as PankoMab 
(Dian et al. 2013; Jeschke et al. 2012) and THRα staining 
in the nucleus (cc = 0.279, p = 0.001). In contrast, THRα1 
expression in the cytoplasm is negatively correlated with 
TA-MUC1 (cc = -0.195, p = 0.019). TA-MUC1 as mem-
brane bound protein can also be translocated to the cyto-
plasm of tumor cells (Heublein et al. 2015). In that case, 
it is negatively correlated with the expression of THRα1 
in the nucleus (cc = − 0.166, p = 0.048) and THRα2 in the 
nucleus (cc = − 0.268, p = 0.001). An immunosuppressive 
glycoprotein that is connected to TA-MUC1 is glycodelin 
and its specific glycoform glycodelin A (Lenhard et al. 2013; 
Scholz et al. 2012). Glycodelin A showed a positive correla-
tion with THRα2 in the cytoplasm (cc = 0.170, p = 0.037). 
Glycodelin showed positive correlation with THRα in the 
nucleus (cc = 0.241, p = 0.003) as well as in the cytoplasm 
(cc = 0.231, p = 0.004). THRα2 expression in the nucleus is 
positively correlated with glycodelin (cc = 0.265, p = 0.001).
Survival analyses
The expression of the general THRα is connected to sig-
nificantly reduced overall survival in the subgroup of clear 
cell carcinomas. The median survival for THRα-negative 
patients is 5.24 years in contrast to only 0.29 years for 
patients showing THRα expression in the nucleus (Fig. 2a, 
p = 0.006).
The THRα isoforms –  α1 and –  α2 are in general 
positive prognosticators if expressed in the nucleus and 
negative prognosticator if expressed in the cytoplasm, 
respectively. In detail, THRα1 is a general positive prog-
nosticator if expressed in the nucleus with a median sur-
vival of 4.22 years for patients positive for THRα1 and 
2.08 years for patients that do not express THRα1 in the 
nucleus (Fig. 2b, p = 0.024). Subgroup analyses of mucinous 
carcinomas showed that THRα1 is a negative prognostica-
tor if expressed in the cytoplasm. The median survival time 
is 16.59 years for mucinous carcinoma patients that do not 
express THRα1 in the cytoplasm and 2.87 years for muci-
nous carcinoma patients with cytoplasmic THRα1 expres-
sion (Fig. 2c, p = 0.037).
The THRα2 receptor in general is a negative prognos-
ticator if expressed in the cytoplasm. The median survival 
time is 3.75 years for patients and 1.37 years for patients 
with THRα2 in the cytoplasm (Fig. 2d, p = 0.001). Nuclear 
expression of THRα2 is not a general positive prognosti-
cator. This can be found in the subgroup of serous high-
grade carcinomas. The mean survival time for high-grade 
serous carcinoma patients with nuclear THRα2 expression 
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is 6.21 years in contrast to 2.32 years for patients with no 
nuclear THRα2 expression (Fig. 2e, p = 0.002). It is remark-
able that patients with clear cell carcinomas show opposite 
results. The median survival time for clear cell carcinoma 
patients with nuclear THRα2 expression is only 1.65 years 
in contrast to 5.24 years for patients with no nuclear THRα2 
expression (Fig. 2f, p = 0.034).
The results of the survival analyses in correlation with 
the histological subtype and staining localization of THRα, 
THRα1 and THRα2 are summarized in Table 2.
Fig. 2  Kaplan–Meier estimates of THRα expression, THRα1 expres-
sion and THRα2 expression were analyzed. In the clear cell subtype, 
patients with a high nuclear expression of THRα showed a signifi-
cantly reduced overall survival compared with patients with a low 
nuclear expression (a). In addition, high nuclear THRα1 expression 
was associated with significantly better overall survival in all ovar-
ian cancer subtypes compared to patients with a low nuclear THRα1 
expression (b). Patients with high THRα1 expression in the cyto-
plasm and mucinous subtype had a significantly decreased overall 
survival compared with those mucinous carcinoma patients with low 
cytoplasmic expression (c). High cytoplasmic THRα2 expression was 
associated with a significantly reduced overall survival in all ovarian 
cancer subtypes compared to patients with a low cytoplasmic THRα2 
expression (d). In the serous subtype, patients with a high nuclear 
expression of THRα2 showed a significantly better overall survival 
compared with patients with a low nuclear expression (e). Finally, 
in the clear cell subtype, patients with a high nuclear expression of 
THRα showed a significantly reduced very low overall survival (all 
patients deceased within two years) compared to patients with a low 
nuclear expression (f)
Table 2  Results of the survival 
analyses in correlation to 
the histological subtype and 
staining localization of THRα, 
THRα1 and THRα2







Nucleus Nucleus Cytoplasm Nucleus Cytoplasm
Total (n = 156) n.s pos. pro. p = 0.024 n.s n.s neg. pro
p = 0.001
High-grade serous (n = 84) n.s n.s n.s pos. pro
p = 0.002
n.s
Low-grade serous (n = 26) n.s n.s n.s n.s n.s
Endometrioid (n = 21) n.s n.s n.s n.s n.s
Mucinous (n = 13) n.s n.s neg. pro
p = 0.037
n.s n.s
Clear cell (n = 12) neg. pro
p = 0.006
n.s n.s neg. pro
p = 0.034
n.s
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Comparison of THRα, − α1 and − 2 expression 
in low‑grade and high‑grade serous ovarian cancer
As shown in Fig. 3, the expression of all three α-subunits 
is higher in the nucleus of low-grade serous ovarian can-
cer cases with a trend to significance in the general THRα 
(p = 0.078), no significance for THRα1 and a significantly 
higher THRα2 expression in low-grade serous cancer cases 
compared to high-grade subtype (the receiver operating 
characteristic curve (ROC) analyses were performed to 
calculate the optimal cut-off values between low and high 
expression of the different THRs).
Cox regression analyses of survival
Cox regression was performed to identify independent pre-
dictors for OS. Pattern of age at surgery failed to remain 
significant within multivariate testing; while grading, FIGO 
staging, THRα1 in the nucleus (Table 3A, p = 0.043) and 
THRα2 in the cytoplasm (Table 3B, p = 0.002) were still 
predictive in multivariate testing sets regarding all subtypes 
of the study group. Due to missing clinical data in single 
cases, cox regression analyses were available in 146 out of 
156 cases.
Discussion
Within this study, we analysed the prognostic value of the 
thyroid hormone receptor alpha forms 1 and 2. The general 
THRα has prognostic value only in clear cell carcinomas, 
where it is expressed at the highest immune scores. The dif-
ferential analyses of nuclear versus cytoplasmic expression 
of THRα1 and THRα2 revealed striking differences con-
cerning the overall survival of ovarian cancer patients. The 
thyroid hormone receptor alpha (THRα) exhibits a dual role 
as an activator or repressor of gene transcription. Former 
studies showed that THRα, formerly thought to reside solely 
in the nucleus and tightly bound to the DNA, shuttles rapidly 
between the nucleus and the cytoplasm (Bunn et al. 2001; 
Maruvada et al. 2003).
The role of thyroid hormones and its receptors was not 
very well understood in ovarian cancer biology for a longer 
time, only very recent publication showed their tremendous 
roles for this deadly disease.
Early investigations with ovarian cancer cell lines and 
T3, T4 and reversed T3 stimulation did not result in suf-
ficient stimulation or inhibition outcomes (Martinez et al. 
2000). Later, it was found that messenger RNA transcripts 
for THRα1, THRα2, T3 activating deiodinase 2 and inac-
tivating deiodinase 3 are present in primary ovarian sur-
face epithelial cell cultures (Rae et al. 2007). A more recent 
study described that for ovarian cancer patients, conflicting 
results were observed for T3 and T4 levels in the serum. 
Insignificant differences were found for T3 (p = 0.209) and 
T4 (p = 0.050) as compared to controls (Rasool et al. 2014).
An actual study described that αvβ3 integrin, a plasma 
membrane receptor that binds the thyroid hormones T3 and 
T4, is overexpressed in ovarian cancer (Shinderman-Maman 
et al. 2016). Both hormones induced cell proliferation and 
significantly reduced the expression of genes that inhibit cell 
cycle particularly in ovarian cancer cells (OVCAR-3) with 
high integrin expression (Shinderman-Maman et al. 2016). 
The same group studied the expression of fifteen genes 
involved in DNA repair, cell cycle, apoptosis, and tumor sup-
pression in OVCAR-3 and A2780 cell lines, using real-time 
PCR following short incubation with T3 or T4 (Shinderman-
Maman et al. 2018). The thyroid hormones downregulated 
the expression of the majority of genes examined, showing 
that these hormones influence the expression of cancer-
relevant genes in ovarian cancer (Shinderman-Maman et al. 
2018). The same group hypothesized that natural thyroid hor-
mone derivatives may antagonize these actions. The three 
antagonists, tetraiodoacetic acid (tetrac), triiodothyroacetic 
Fig. 3  Comparison of immunohistochemical staining results of the 
different THR (median values) in the nucleus of the high- and low-
grade serous ovarian cancer subtypes. (IRS Immunoreactive Score, 
THR: Thyroid Receptor). The expression of THRα2 in the nucleus 
is significantly different in low-grade compared to high-grade serous 
carcinomas (marked by an asterisk)
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acid (triac) and 3-iodothyronamine (T1AM) inhibited cell 
proliferation and induced cell death and DNA damage in the 
two ovarian cancer cell lines (OVCAR3 and A2780). There-
fore, they concluded that the cytotoxic potential of thyroid 
hormone derivatives, tetrac, triac and T1AM, in ovarian can-
cer might provide a much-needed novel therapeutic approach 
(Shinderman-Maman et al. 2017).
Based on the results of the former study, another group 
described that thyroid hormone causes elevated phospho-
rylation and nuclear enrichment of ERα (Hsieh et al. 2017). 
In addition, confocal microscopy indicated that both T4 
and estradiol caused nuclear translocation of integrin αv 
and phosphorylation of ERα (Hsieh et al. 2017). Within our 
study, we found a positive correlation between the THRα2 
in the nucleus and ERα. We also found positive correlation 
of THRα in the nucleus and ERβ, assuming that thyroid 
hormones not only elevate the nuclear enrichment of ERα 
but also might influence ERβ. However, our correlations 
referred to the whole study cohort and did not focus on the 
histological subtypes. Another study showed that THRα1 
inhibits the ERα transactivation from the consensus estro-
gen response element (ERE). In contrast, the ligand bound 
THRβ1 facilitates ERβ-mediated transactivation (Vasudevan 
et al. 2001). We also found a positive correlation between 
the GPER and THRα. Sheng et al. showed that the GPER 
together with integrin αvβ3 participate in the induction of 
male germ cell proliferation and thyroid transcription dis-
ruption after low-dose Bisphenol A treatment (Sheng et al. 
2019). Another correlation of our study was found between 
THRα in the nucleus and the FSH receptor; whereas, the 
THRα expression in the cytoplasm showed a positive cor-
relation to the LH/hCG receptor. It has been known for a 
longer time that LH, FSH, and TSH show low-level cross-
reactivity between their respective receptors (Tonacchera 
et al. 2006). Vissenberg et al. explained that T3 in combi-
nation with FSH enhances granulosa cell proliferation and 
inhibits granulosa cell apoptosis by the PI3K/Akt pathway 
(Vissenberg et al. 2015). They also described that T3 is con-
sidered a biological amplifier of the stimulatory action of 
gonadotrophins on granulosa cell function (Vissenberg et al. 
2015). Because the exclusive expression of the FSHR has 
already been described by our group as a negative prognos-
ticator in ovarian cancer cases, our finding about enhanced 
expression of both FSHR and THRα in the nucleus might 
lead to new treatment strategies for this type of cancer (Len-
hard et al. 2011). This assumption might also apply for the 
antibody Gatipotuzumab and its TA-MUC1 epitope (Heu-
blein et al. 2019), which showed an inverse correlation to 
THRα1 and -2 expression either in the nucleus or in the 
cytoplasm, respectively.
Table 3  Multivariate survival 
analyses with the overall 
survival time for (A) THRα1 
expression in the nucleus, 
(B) THRα2 expression in the 
cytoplasm, regarding patients 
age, histological subtype, 
grading, and staging (n = 146)




 IRS > 0 versus IRS 0 0.049 0.618 0.383 0.997
FIGO
 I/II versus III/IV 0.001 2.761 1.510
Grading
 G1/low grade versus 0.002 2.753 1.457 5.199
 G2/3/high grade
Histological subtype
 all subtypes versus high-grade serous 0.964 0.994 0.783 1.263
Age
  < 60 versus ≥ 60 years 0.116 0.717 0.473 1.085
(B) THRα2 (cytoplasm)
 IRS > 0 versus IRS 0 0.002 2.790 1.466 5.310
Age
  < 60 versus ≥ 60 years 0.212 0.769 0.509 1.161
Histological subtype
 all other subtypes versus high-grade serous 0.673 0.950 0.747 1.207
Grading
 G1/low-grade versus 0.001 0.325 0.171 0.618
 G2/3/high-grade
FIGO
 I/II versus III/IV 0.001 0.365 0.201 0.662
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In addition, T4 has been shown to promote ovarian can-
cer cell proliferation via integrin αvβ3. T4 also induced 
the activation of ERK1/2 and expression of programmed 
death-ligand 1 (PD-L1) in ovarian cancer cells (Chin et al. 
2018). In contrast, resveratrol binds to integrin αvβ3 at 
a discrete site and induces p53-dependent anti-prolifera-
tion in malignant neoplastic cells. T4 impairs resveratrol-
induced anti-proliferation in human ovarian cancer cells 
and T4 inhibited resveratrol-induced nuclear accumulation 
of COX-2 (Chin et al. 2018). Furthermore, T4 increased 
expression and cytoplasmic accumulation of PD-L1, which 
in turn acted to retain inducible COX-2 in the cytoplasm 
(Chin et al. 2018). Thus, T4 inhibits COX-2-dependent 
apoptosis in ovarian cancer cells by retaining inducible 
COX-2 with PD-L1 in the cytoplasm (Chin et al. 2018).
Recently, the interplay between epithelial–mesenchymal 
transition (EMT) and the thyroid hormones-αvβ3 axis in 
ovarian cancer was investigated (Weingarten et al. 2018). It 
was shown that the transcription of mesenchymal markers, 
β-catenin, zeb-1, slug/snail, vimentin, and n-cadherin was 
hardly affected by T3 and T4, while that of the epithelial mark-
ers, e-cadherin and zo-1, and was inhibited after treatment with 
thyroid hormones. These results suggest a novel role for the 
thyroid hormone-αvβ3 axis in EMT, with possible implications 
for ovarian cancer metastasis (Weingarten et al. 2018).
Finally, a group investigated the role of the thyroid 
hormone receptor Interactor 13 (TRIP13) in epithelial 
ovarian cancer (EOC) (Zhou and Shu, 2019). Bioinfor-
matics analysis showed that TRIP13 was one of the most 
significantly upregulated proteins in EOC. Results of the 
described study showed that TRIP13 acted as an onco-
promotive regulator in EOC development by modulating 
the Notch signaling pathway (Zhou and Shu, 2019).
A large demographic study, the “Ovarian Cancer Associa-
tion Consortium”, showed that hyperthyroidism within the 
5 years before ovarian cancer diagnosis was associated with 
an increased risk of death (Minlikeeva et al. 2017). These 
very recent results were accompanied by the fact that a more 
modest association was observed with the history of hypothy-
roidism (n = 624 cases) and mortality (Minlikeeva et al. 2017).
In sum, the results of the experimental and demographic 
studies about the roles of thyroid hormones, its receptors and 
interacting proteins. There is growing body of evidence that 
they play a major role in ovarian cancer biology and survival 
of ovarian cancer patients. Only recent studies were able to 
bring new light into this area of research.
Conclusions
With our study, we could show that there is a direct link 
between nuclear expression of THRα1 or − 2 and bet-
ter survival in EOC, except for the subgroup of clear cell 
carcinomas. The latter group seems to have different proper-
ties concerning THRα expression. Shifting the expression 
of THRα1 or − 2 to the cytoplasm seems to be connected 
with reduced overall survival in EOC cases. Therefore, the 
search for THRα interacting factors that prevent this shift 
to the cytoplasm seems to be a useful new approach for the 
search of future treatment strategies against the threatening 
disease of Epithelial Ovarian Cancer.
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